As longevity risk attracts increasing attention among pension funds, market participants are questioning reinsurers’ capacity to cope with the growing demand, and are looking for alternative solutions. Pharmaceutical and care homes could provide the answer, according Swiss Re.
Daniel Ryan, head of life and health research at Swiss Re, suggests the nature of both industries means they could benefit from increasing longevity, making them ideal counterparties for longevity swap deals. “There are ce
The week on Risk.net, December 2–8, 2017Receive this by email